A structural map of KRAS(G12C), showing the AMG 510 molecule in the binding pocket. Amgen is a Participating Research Team member of the Berkeley Center for Structural Biology (BCSB), which maintains and operates five of the ALS beamlines. (Credit: Amgen)
An investigational cancer drug that targets tumors caused by mutations in the KRAS gene will be evaluated in phase 2 clinical trials, following promising safety and efficacy results in preliminary human studies and excellent results in animal studies.
The drug, developed by Amgen and currently referred to as AMG 510, is the first therapy to reach clinical trials that inhibits a mutant KRAS protein. Errors in the KRAS gene, which encodes a crucial cell signaling protein, are one of the most common causes of cancer.
The particular mutant inhibited by AMG 510 – called KRAS(G12C) – is present in approximately 13% of lung adenocarcinomas, 3% of colorectal cancers, and 2% of other solid tumors.
Despite its significant role in the pathogenesis of cancer, scientists have been unable to design KRAS-specific therapeutics due to the shape of the protein – it has an exceptionally smooth surface with no obvious regions for a drug molecule to bind. Seeking to develop a long-sought direct inhibitor, researchers at Amgen conducted X-ray crystallography of KRAS(G12C) proteins at Berkeley Lab’s Advanced Light Source (ALS). The high-resolution structural maps generated using the data acquired at the beamlines helped Amgen make the breakthrough discovery of a small pocket on the molecule. In subsequent studies, the beamline data allowed scientists to investigate atomic-level molecular interactions between KRAS(G12C) and potential inhibiting compounds that bind in this pocket. AMG 510 emerged as a very promising candidate after a multiyear drug agent optimization program.
“It’s rare that a compound gets all the way through the development process and becomes a drug. So, for the BCSB team, it feels great to see our (small) contribution finding its way to fight diseases,” said Marc Allaire, one of the Berkeley Lab biophysicists who operate the BCSB beamlines.
Learn more: Unique Cancer Drug Discovered With Help From Advanced Light Source Begins Historical Clinical Trial
Go deeper with Bing News on:
Investigational cancer drug
- Helsinn presents newly available data on vepafestinib at IASLC 2022 World Conference on Lung Cancer
Helsinn presents newly available data on vepafestinib. at IASLC 2022 World Conference on Lung Cancer. Lugano, Switzerland, August 8, 2022 - Helsinn Group (“Helsinn”), a fully ...
- HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer
Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that the pivotal global Phase 3 FRESCO-2 trial evaluating the investigational use of fruquintinib met its primary endpoint of overall ...
- New Cancer Drug Combination Reduced Risk of Death by 31%
When compared to standard treatment, the combination of ramucirumab and pembrolizumab decreased the risk of mortality by 31% in patients with advanced non-small cell lung cancer that had progressed on ...
- FDA Clears IND Application for AVB-001 in Relapsed/Refractory Ovarian Cancer
The FDA accepted an investigational new drug application allowing for the start of a phase 1 trial to evaluate the tolerability of AVB-101 in patients with platinum resistance ovarian cancer.
- Patients with advanced cancer set to benefit from ProfoundBio’s new drug
Patients with ovarian, endometrial, breast, non-small cell lung cancers and mesothelioma could benefit from an antibody drug conjugate.
Go deeper with Google Headlines on:
Investigational cancer drug
Go deeper with Bing News on:
Cancer drug
- Meet The Scientist Coordinating Joe Biden’s New Cancer Moonshot
Dr. Danielle Carnival, White House Cancer Moonshot Coordinator, speaks at the Call-on ... [+] Congress-United in Blue rally and installation on the National Mall for Colorectal Cancer Awareness Month ...
- FDA Approves Expanded Use For Bayer's Prostate Cancer Drug
The FDA approved Bayer AG's (OTC: BAYRY) supplemental marketing application for Nubeqa (darolutamide) with docetaxel for metastatic hormone-sensitive prostate cancer (mHSPC). The approval is based on ...
- Break Through Barriers To Drive Progress: Cancer Moonshot Pathways
President Joe Biden in February launched a “Cancer Moonshot” initiative that aims to reduce the death rate from cancer by 50% in the next 25 years. How can it be achieved?
- HUTCHMED drug in colorectal cancer trial meets primary endpoint
A trial to look at the use of a drug targeting refractory metastatic colorectal cancer (CRC) has met its primary endpoint.
- Abortion bans complicate access to drugs for cancer, arthritis, even ulcers
Medicines that treat conditions from cancer to autoimmune diseases to ulcers can also end a pregnancy or cause birth defects. As a result, doctors and pharmacists in more than a dozen states with ...
